EHNAC releases 2010 criteria for accreditation programs

Nonprofit standards development organization Electronic Healthcare Network Accreditation Commission (EHNAC) has set the adoption of program criteria for 2010 accreditation programs.

Concluding a 60-day public comment period, the Farmington, Conn.-based EHNAC has finalized and adopted the enhanced criteria versions for the following programs:
    • ASPAP-EHR – Application Service Provider Accreditation Program for EHRs
    • ePAP – e-prescribing Accreditation Program
    • FSAP EHN – Financial Services Accreditation Program for Electronic Health Networks
    • FSAP Lockbox – Financial Services Accreditation Program for Lockbox Services
    • HNAP EHN – Healthcare Network Accreditation Program for Electronic Health Networks
    • HNAP Medical Biller – Healthcare Network Accreditation Program for Medical Billers
    • HNAP TPA – Healthcare Network Accreditation Program for TPAs
    • HNAP-70 – Healthcare Network Accreditation Plus Select SAS 70 Criteria Program
    • OSAP – Outsourced Services Accreditation Program

      According to EHNAC, the oganization has developed a separate set of draft criteria related to the Health IT for Economic and Clinical Health (HITECH) Act that will be incorporated into each program’s criteria when federal regulations are finalized.

      Additionally, EHNAC is in the process of developing draft criteria for health information exchange (HIE) entities and has been facilitating industry collaboration on the content. According to EHNAC, the HIE draft criteria is expected to be released for 60-day public comment and review in February and finalized during the second quarter.

      Around the web

      The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

      The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

      Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.